Noel Mueller
Concepts (507)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 29 | 2026 | 773 | 9.330 |
Why?
| | Microbiota | 17 | 2026 | 736 | 5.070 |
Why?
| | Cesarean Section | 14 | 2025 | 230 | 4.620 |
Why?
| | Delivery, Obstetric | 10 | 2022 | 164 | 3.680 |
Why?
| | Fatty Acids, Volatile | 8 | 2025 | 60 | 3.180 |
Why?
| | Pre-Eclampsia | 7 | 2025 | 206 | 2.970 |
Why?
| | Blood Pressure | 19 | 2026 | 1785 | 2.760 |
Why?
| | Adiposity | 11 | 2024 | 533 | 2.760 |
Why?
| | Feces | 13 | 2026 | 500 | 2.740 |
Why?
| | Trace Elements | 4 | 2021 | 52 | 2.530 |
Why?
| | Pediatric Obesity | 13 | 2025 | 638 | 2.500 |
Why?
| | Hypertension | 13 | 2026 | 1280 | 2.400 |
Why?
| | Vagina | 8 | 2026 | 206 | 2.400 |
Why?
| | Body Mass Index | 30 | 2025 | 2466 | 2.380 |
Why?
| | Menarche | 7 | 2023 | 53 | 2.360 |
Why?
| | Pregnancy | 43 | 2026 | 7276 | 2.120 |
Why?
| | Milk, Human | 3 | 2026 | 176 | 2.040 |
Why?
| | Metals, Heavy | 3 | 2021 | 31 | 1.900 |
Why?
| | Prenatal Exposure Delayed Effects | 10 | 2024 | 663 | 1.870 |
Why?
| | Mothers | 14 | 2026 | 774 | 1.820 |
Why?
| | Dietary Approaches To Stop Hypertension | 5 | 2026 | 14 | 1.800 |
Why?
| | Metabolome | 4 | 2026 | 391 | 1.640 |
Why?
| | Diabetes Mellitus, Type 2 | 15 | 2026 | 2627 | 1.550 |
Why?
| | Infant, Newborn | 26 | 2026 | 6543 | 1.510 |
Why?
| | Breast Feeding | 5 | 2026 | 447 | 1.490 |
Why?
| | Female | 113 | 2026 | 80054 | 1.480 |
Why?
| | Metformin | 5 | 2022 | 329 | 1.400 |
Why?
| | Dietary Fiber | 3 | 2023 | 59 | 1.390 |
Why?
| | Infant | 30 | 2026 | 10195 | 1.340 |
Why?
| | Humans | 145 | 2026 | 147265 | 1.320 |
Why?
| | Fetal Blood | 4 | 2022 | 327 | 1.290 |
Why?
| | Carbonated Beverages | 3 | 2015 | 16 | 1.220 |
Why?
| | Dietary Carbohydrates | 3 | 2021 | 147 | 1.190 |
Why?
| | Dietary Proteins | 2 | 2020 | 135 | 1.120 |
Why?
| | Premature Birth | 2 | 2023 | 390 | 1.100 |
Why?
| | Prospective Studies | 24 | 2026 | 8165 | 1.100 |
Why?
| | Diet, Sodium-Restricted | 4 | 2026 | 39 | 1.070 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 2218 | 1.040 |
Why?
| | Obesity | 15 | 2022 | 3144 | 1.030 |
Why?
| | Longevity | 2 | 2019 | 178 | 1.020 |
Why?
| | Methylamines | 2 | 2024 | 39 | 0.960 |
Why?
| | Diet | 15 | 2024 | 1282 | 0.960 |
Why?
| | Male | 81 | 2026 | 73928 | 0.950 |
Why?
| | Child | 37 | 2026 | 22960 | 0.930 |
Why?
| | Longitudinal Studies | 14 | 2026 | 3029 | 0.910 |
Why?
| | Non-Nutritive Sweeteners | 2 | 2015 | 7 | 0.910 |
Why?
| | Adult | 58 | 2024 | 41404 | 0.880 |
Why?
| | Bacteria | 6 | 2026 | 769 | 0.870 |
Why?
| | Health Impact Assessment | 2 | 2022 | 7 | 0.870 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2024 | 85 | 0.820 |
Why?
| | Selenium | 2 | 2021 | 50 | 0.810 |
Why?
| | Sugars | 1 | 2023 | 40 | 0.780 |
Why?
| | Insulin Resistance | 6 | 2022 | 1252 | 0.780 |
Why?
| | Manganese | 2 | 2020 | 59 | 0.770 |
Why?
| | Air Pollution | 3 | 2022 | 315 | 0.770 |
Why?
| | Anti-Bacterial Agents | 5 | 2020 | 1940 | 0.770 |
Why?
| | Infant Nutritional Physiological Phenomena | 3 | 2020 | 159 | 0.770 |
Why?
| | Risk Factors | 34 | 2024 | 11016 | 0.760 |
Why?
| | Leg | 2 | 2015 | 243 | 0.760 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 62 | 0.740 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2024 | 512 | 0.730 |
Why?
| | Child, Preschool | 18 | 2026 | 12011 | 0.720 |
Why?
| | Blood Pressure Determination | 3 | 2019 | 145 | 0.710 |
Why?
| | Diet, Mediterranean | 1 | 2022 | 27 | 0.700 |
Why?
| | Body Composition | 3 | 2025 | 689 | 0.700 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 6003 | 0.690 |
Why?
| | Birth Weight | 7 | 2024 | 522 | 0.670 |
Why?
| | HTLV-I Infections | 10 | 2000 | 29 | 0.670 |
Why?
| | Chorioamnionitis | 1 | 2021 | 50 | 0.670 |
Why?
| | Hypotension | 1 | 2022 | 127 | 0.660 |
Why?
| | Overweight | 10 | 2021 | 613 | 0.660 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 52 | 0.640 |
Why?
| | Fats, Unsaturated | 1 | 2020 | 1 | 0.630 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2020 | 24 | 0.610 |
Why?
| | Flatulence | 1 | 2019 | 2 | 0.600 |
Why?
| | Weight Gain | 3 | 2018 | 566 | 0.590 |
Why?
| | Dyspepsia | 1 | 2019 | 11 | 0.590 |
Why?
| | Body Fluids | 1 | 2019 | 71 | 0.590 |
Why?
| | Androgens | 1 | 2020 | 181 | 0.580 |
Why?
| | Pressure | 1 | 2020 | 228 | 0.570 |
Why?
| | Abdominal Pain | 1 | 2020 | 149 | 0.550 |
Why?
| | Cohort Studies | 14 | 2023 | 6095 | 0.550 |
Why?
| | Vitamin D Deficiency | 1 | 2020 | 190 | 0.550 |
Why?
| | Boston | 6 | 2021 | 93 | 0.540 |
Why?
| | Bayes Theorem | 5 | 2024 | 428 | 0.540 |
Why?
| | Disinfectants | 1 | 2018 | 45 | 0.540 |
Why?
| | Vitamin D | 2 | 2023 | 405 | 0.540 |
Why?
| | Waist Circumference | 4 | 2016 | 145 | 0.530 |
Why?
| | Estrogens | 1 | 2020 | 368 | 0.520 |
Why?
| | Middle Aged | 41 | 2026 | 36819 | 0.520 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 266 | 0.520 |
Why?
| | Skinfold Thickness | 2 | 2018 | 43 | 0.510 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 780 | 0.500 |
Why?
| | Biomarkers | 5 | 2024 | 4354 | 0.500 |
Why?
| | Age Factors | 6 | 2020 | 3370 | 0.480 |
Why?
| | Asthma | 3 | 2022 | 1805 | 0.480 |
Why?
| | Puberty | 2 | 2014 | 137 | 0.470 |
Why?
| | Absorptiometry, Photon | 3 | 2025 | 277 | 0.470 |
Why?
| | Weight Loss | 5 | 2022 | 867 | 0.460 |
Why?
| | Gastrointestinal Tract | 2 | 2015 | 204 | 0.460 |
Why?
| | Young Adult | 18 | 2021 | 14437 | 0.460 |
Why?
| | Singapore | 5 | 2013 | 27 | 0.450 |
Why?
| | Infant Welfare | 1 | 2014 | 8 | 0.430 |
Why?
| | Adolescent | 24 | 2022 | 22814 | 0.430 |
Why?
| | Brazil | 7 | 2016 | 179 | 0.420 |
Why?
| | Rural Population | 3 | 2018 | 685 | 0.420 |
Why?
| | Abdominal Fat | 1 | 2014 | 51 | 0.420 |
Why?
| | Leptin | 1 | 2016 | 249 | 0.410 |
Why?
| | Adiponectin | 1 | 2016 | 244 | 0.410 |
Why?
| | Health Status | 3 | 2023 | 837 | 0.400 |
Why?
| | Diabetes, Gestational | 2 | 2018 | 307 | 0.400 |
Why?
| | Metabolic Syndrome | 4 | 2021 | 365 | 0.390 |
Why?
| | Intra-Abdominal Fat | 2 | 2024 | 101 | 0.390 |
Why?
| | Baltimore | 2 | 2024 | 72 | 0.390 |
Why?
| | Chronic Disease | 1 | 2019 | 1845 | 0.390 |
Why?
| | Vitamins | 3 | 2024 | 184 | 0.390 |
Why?
| | Glucose | 2 | 2015 | 1051 | 0.380 |
Why?
| | Linear Models | 6 | 2018 | 852 | 0.380 |
Why?
| | Dyslipidemias | 1 | 2015 | 185 | 0.380 |
Why?
| | Parity | 1 | 2013 | 112 | 0.380 |
Why?
| | Feeding Behavior | 2 | 2017 | 691 | 0.380 |
Why?
| | Social Class | 1 | 2015 | 265 | 0.370 |
Why?
| | Anthropometry | 1 | 2013 | 203 | 0.370 |
Why?
| | Fetal Development | 1 | 2016 | 298 | 0.370 |
Why?
| | Wrist | 1 | 2013 | 60 | 0.370 |
Why?
| | Inflammation | 1 | 2024 | 2921 | 0.370 |
Why?
| | Multicenter Studies as Topic | 2 | 2024 | 417 | 0.370 |
Why?
| | Herpesvirus 4, Human | 5 | 1998 | 173 | 0.360 |
Why?
| | Time Factors | 9 | 2024 | 7173 | 0.350 |
Why?
| | Soy Foods | 1 | 2011 | 3 | 0.350 |
Why?
| | Fatty Liver | 1 | 2014 | 257 | 0.350 |
Why?
| | Isoflavones | 1 | 2011 | 25 | 0.350 |
Why?
| | Soybean Proteins | 1 | 2011 | 15 | 0.350 |
Why?
| | Environmental Pollutants | 2 | 2024 | 142 | 0.350 |
Why?
| | Micronutrients | 2 | 2023 | 102 | 0.350 |
Why?
| | Liver | 1 | 2020 | 1916 | 0.350 |
Why?
| | Aged | 23 | 2025 | 26509 | 0.350 |
Why?
| | Gestational Age | 3 | 2021 | 997 | 0.330 |
Why?
| | Butyrates | 2 | 2022 | 66 | 0.330 |
Why?
| | Obesity, Abdominal | 3 | 2016 | 48 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2026 | 1776 | 0.320 |
Why?
| | Social Determinants of Health | 1 | 2015 | 322 | 0.320 |
Why?
| | Renal Dialysis | 2 | 2024 | 467 | 0.310 |
Why?
| | Bifidobacterium | 2 | 2021 | 21 | 0.310 |
Why?
| | Probiotics | 2 | 2021 | 61 | 0.300 |
Why?
| | Maternal Exposure | 2 | 2024 | 190 | 0.300 |
Why?
| | Risk Assessment | 6 | 2024 | 3784 | 0.300 |
Why?
| | Child Health | 2 | 2023 | 154 | 0.300 |
Why?
| | Sodium, Dietary | 4 | 2026 | 43 | 0.290 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 676 | 0.290 |
Why?
| | Hodgkin Disease | 4 | 1998 | 173 | 0.290 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 160 | 0.290 |
Why?
| | Protective Factors | 3 | 2019 | 102 | 0.280 |
Why?
| | Socioeconomic Factors | 7 | 2021 | 1342 | 0.280 |
Why?
| | Follow-Up Studies | 8 | 2018 | 5477 | 0.270 |
Why?
| | Denmark | 2 | 2025 | 51 | 0.270 |
Why?
| | Beverages | 2 | 2023 | 68 | 0.270 |
Why?
| | Papillomavirus Vaccines | 1 | 2012 | 296 | 0.270 |
Why?
| | Case-Control Studies | 7 | 2023 | 3660 | 0.270 |
Why?
| | Women, Working | 2 | 2017 | 11 | 0.260 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 345 | 0.260 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 673 | 0.260 |
Why?
| | Prevalence | 10 | 2024 | 2888 | 0.260 |
Why?
| | Logistic Models | 7 | 2023 | 2141 | 0.250 |
Why?
| | Autism Spectrum Disorder | 2 | 2024 | 425 | 0.250 |
Why?
| | Quality of Life | 1 | 2019 | 3243 | 0.240 |
Why?
| | Body Size | 2 | 2018 | 90 | 0.240 |
Why?
| | Incidence | 7 | 2022 | 2954 | 0.230 |
Why?
| | Infant, Low Birth Weight | 2 | 2016 | 156 | 0.220 |
Why?
| | Quebec | 1 | 2025 | 10 | 0.220 |
Why?
| | City Planning | 2 | 2022 | 3 | 0.220 |
Why?
| | Interviews as Topic | 3 | 2015 | 931 | 0.210 |
Why?
| | Blood Glucose | 5 | 2021 | 2359 | 0.210 |
Why?
| | Emergency Medical Services | 1 | 2012 | 691 | 0.210 |
Why?
| | Canada | 1 | 2026 | 435 | 0.210 |
Why?
| | Pregnancy Trimester, First | 2 | 2024 | 139 | 0.210 |
Why?
| | Infectious Mononucleosis | 2 | 1998 | 10 | 0.210 |
Why?
| | Cities | 2 | 2022 | 140 | 0.210 |
Why?
| | Ohio | 2 | 2015 | 146 | 0.210 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 112 | 0.200 |
Why?
| | Bacteroides fragilis | 1 | 2024 | 14 | 0.200 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2024 | 27 | 0.200 |
Why?
| | Biometry | 1 | 2024 | 66 | 0.200 |
Why?
| | Diet, Vegetarian | 1 | 2024 | 11 | 0.200 |
Why?
| | Folic Acid | 3 | 2024 | 198 | 0.200 |
Why?
| | Pregnancy Complications | 3 | 2024 | 607 | 0.200 |
Why?
| | Sleep | 2 | 2023 | 895 | 0.200 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.200 |
Why?
| | Research Design | 2 | 2021 | 1155 | 0.200 |
Why?
| | Antibodies, Viral | 6 | 1991 | 687 | 0.200 |
Why?
| | Oligosaccharides | 1 | 2024 | 61 | 0.200 |
Why?
| | Homeostasis | 3 | 2016 | 651 | 0.200 |
Why?
| | Mucus | 1 | 2024 | 75 | 0.190 |
Why?
| | Nutrition Assessment | 2 | 2015 | 91 | 0.190 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2974 | 0.190 |
Why?
| | Vitamin A | 1 | 2023 | 62 | 0.190 |
Why?
| | Metals | 1 | 2024 | 138 | 0.190 |
Why?
| | Maternal Age | 1 | 2023 | 129 | 0.190 |
Why?
| | Tryptophan | 1 | 2024 | 183 | 0.190 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1430 | 0.190 |
Why?
| | Phthalic Acids | 1 | 2022 | 43 | 0.180 |
Why?
| | Aging | 2 | 2024 | 1992 | 0.180 |
Why?
| | Cannabidiol | 1 | 2024 | 142 | 0.180 |
Why?
| | District of Columbia | 3 | 2021 | 38 | 0.180 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 234 | 0.180 |
Why?
| | Hepatitis C | 3 | 2000 | 256 | 0.170 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 72 | 0.170 |
Why?
| | Regression Analysis | 3 | 2012 | 1002 | 0.170 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2021 | 32 | 0.170 |
Why?
| | Dronabinol | 1 | 2024 | 251 | 0.170 |
Why?
| | Sodium | 2 | 2021 | 198 | 0.170 |
Why?
| | Urban Health | 1 | 2022 | 96 | 0.170 |
Why?
| | HTLV-I Antibodies | 5 | 1992 | 6 | 0.170 |
Why?
| | Obesity Management | 1 | 2021 | 12 | 0.170 |
Why?
| | Glycemic Index | 1 | 2021 | 26 | 0.170 |
Why?
| | Permeability | 1 | 2022 | 170 | 0.170 |
Why?
| | Cardiovascular System | 1 | 2023 | 139 | 0.170 |
Why?
| | Purines | 1 | 2022 | 188 | 0.170 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 947 | 0.170 |
Why?
| | Smoking | 4 | 2013 | 1483 | 0.170 |
Why?
| | Clostridium perfringens | 1 | 2021 | 5 | 0.170 |
Why?
| | Clostridium | 1 | 2021 | 19 | 0.170 |
Why?
| | Oxides | 1 | 2021 | 47 | 0.170 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 133 | 0.170 |
Why?
| | Bacteroides | 1 | 2021 | 20 | 0.170 |
Why?
| | Growth | 1 | 2021 | 49 | 0.160 |
Why?
| | Registries | 2 | 2024 | 2434 | 0.160 |
Why?
| | Sex Characteristics | 2 | 2016 | 799 | 0.160 |
Why?
| | Odds Ratio | 6 | 2023 | 1083 | 0.160 |
Why?
| | Glomerular Filtration Rate | 1 | 2024 | 765 | 0.160 |
Why?
| | Minority Groups | 1 | 2022 | 286 | 0.160 |
Why?
| | Uric Acid | 1 | 2021 | 168 | 0.160 |
Why?
| | Postpartum Period | 1 | 2023 | 379 | 0.150 |
Why?
| | Skin Absorption | 1 | 2019 | 14 | 0.150 |
Why?
| | Dysbiosis | 1 | 2021 | 188 | 0.150 |
Why?
| | Models, Statistical | 1 | 2024 | 677 | 0.150 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 84 | 0.150 |
Why?
| | Massachusetts | 1 | 2020 | 181 | 0.150 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 26 | 0.150 |
Why?
| | Vulnerable Populations | 1 | 2021 | 177 | 0.150 |
Why?
| | Digestive System | 1 | 2019 | 29 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2024 | 1225 | 0.150 |
Why?
| | Sex Factors | 4 | 2019 | 2133 | 0.150 |
Why?
| | Appetite | 1 | 2020 | 80 | 0.150 |
Why?
| | Mercury | 1 | 2019 | 41 | 0.150 |
Why?
| | Cadmium | 1 | 2019 | 68 | 0.150 |
Why?
| | Cost of Illness | 1 | 2022 | 327 | 0.150 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2021 | 318 | 0.150 |
Why?
| | Cholesterol, HDL | 1 | 2020 | 202 | 0.140 |
Why?
| | Venezuela | 1 | 2018 | 7 | 0.140 |
Why?
| | Lead | 1 | 2019 | 71 | 0.140 |
Why?
| | Men's Health | 1 | 2018 | 6 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2019 | 208 | 0.140 |
Why?
| | Employment | 2 | 2017 | 184 | 0.140 |
Why?
| | DNA, Bacterial | 1 | 2020 | 320 | 0.140 |
Why?
| | Age Distribution | 2 | 2018 | 406 | 0.140 |
Why?
| | United States | 8 | 2023 | 16313 | 0.140 |
Why?
| | Behavior Therapy | 1 | 2021 | 297 | 0.140 |
Why?
| | Nutritional Status | 2 | 2024 | 349 | 0.140 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 1991 | 124 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 863 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2024 | 600 | 0.130 |
Why?
| | Skin | 1 | 2023 | 759 | 0.130 |
Why?
| | Dizziness | 1 | 2019 | 101 | 0.130 |
Why?
| | Cholesterol, LDL | 1 | 2020 | 363 | 0.130 |
Why?
| | Age of Onset | 2 | 2016 | 568 | 0.130 |
Why?
| | Nutrition Surveys | 2 | 2021 | 279 | 0.130 |
Why?
| | Reference Values | 1 | 2019 | 798 | 0.130 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2018 | 85 | 0.130 |
Why?
| | Health Status Disparities | 1 | 2021 | 323 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 6161 | 0.130 |
Why?
| | Infant, Small for Gestational Age | 1 | 2018 | 118 | 0.130 |
Why?
| | Public Health | 2 | 2021 | 576 | 0.130 |
Why?
| | Verrucomicrobia | 1 | 2016 | 4 | 0.120 |
Why?
| | Leukocytes | 1 | 2018 | 301 | 0.120 |
Why?
| | Colombia | 2 | 2016 | 42 | 0.120 |
Why?
| | Computational Biology | 1 | 2021 | 677 | 0.120 |
Why?
| | Japan | 6 | 2000 | 149 | 0.120 |
Why?
| | Confidence Intervals | 2 | 2012 | 329 | 0.120 |
Why?
| | Income | 1 | 2017 | 208 | 0.120 |
Why?
| | Developing Countries | 2 | 2017 | 318 | 0.120 |
Why?
| | Disease Progression | 1 | 2024 | 2892 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1072 | 0.120 |
Why?
| | Death | 1 | 2017 | 132 | 0.120 |
Why?
| | Phylogeny | 1 | 2020 | 924 | 0.120 |
Why?
| | Preconception Care | 1 | 2016 | 50 | 0.110 |
Why?
| | Aspartame | 1 | 2015 | 5 | 0.110 |
Why?
| | Liver Neoplasms | 2 | 2000 | 787 | 0.110 |
Why?
| | Intestines | 1 | 2018 | 356 | 0.110 |
Why?
| | Pandemics | 2 | 2021 | 1719 | 0.110 |
Why?
| | Coffee | 1 | 2015 | 16 | 0.110 |
Why?
| | Epidemiologic Methods | 2 | 2013 | 91 | 0.110 |
Why?
| | Particulate Matter | 1 | 2018 | 329 | 0.110 |
Why?
| | Nutrition Policy | 1 | 2015 | 57 | 0.110 |
Why?
| | Caffeine | 1 | 2015 | 76 | 0.110 |
Why?
| | China | 1 | 2015 | 278 | 0.110 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2015 | 105 | 0.110 |
Why?
| | Body Weight | 1 | 2019 | 971 | 0.110 |
Why?
| | Animals | 8 | 2024 | 38416 | 0.110 |
Why?
| | Dietary Supplements | 3 | 2024 | 586 | 0.110 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 203 | 0.100 |
Why?
| | Organ Size | 1 | 2015 | 465 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2024 | 11944 | 0.100 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1344 | 0.100 |
Why?
| | Immunoglobulin M | 3 | 1991 | 267 | 0.100 |
Why?
| | California | 1 | 2015 | 477 | 0.100 |
Why?
| | Physical Examination | 1 | 2015 | 245 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1549 | 0.100 |
Why?
| | Cross-Over Studies | 2 | 2026 | 615 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2015 | 1300 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4384 | 0.100 |
Why?
| | Glucose Metabolism Disorders | 1 | 2012 | 10 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2019 | 1368 | 0.090 |
Why?
| | Diabetic Angiopathies | 1 | 2014 | 267 | 0.090 |
Why?
| | Central America | 1 | 2012 | 28 | 0.090 |
Why?
| | Sarcoma, Kaposi | 2 | 1997 | 83 | 0.090 |
Why?
| | Capsid Proteins | 2 | 1991 | 94 | 0.090 |
Why?
| | South America | 1 | 2012 | 56 | 0.090 |
Why?
| | Area Under Curve | 1 | 2012 | 334 | 0.090 |
Why?
| | Abdomen | 1 | 2012 | 142 | 0.090 |
Why?
| | Demography | 3 | 2017 | 283 | 0.080 |
Why?
| | Brain | 1 | 2023 | 3009 | 0.080 |
Why?
| | Antigens, Viral | 3 | 1999 | 186 | 0.080 |
Why?
| | Cytokines | 1 | 2018 | 2087 | 0.080 |
Why?
| | Immunoglobulin G | 3 | 1991 | 901 | 0.080 |
Why?
| | ROC Curve | 1 | 2012 | 626 | 0.080 |
Why?
| | Carrier State | 3 | 1998 | 79 | 0.080 |
Why?
| | Occupations | 3 | 2017 | 51 | 0.080 |
Why?
| | Dietary Sucrose | 1 | 2010 | 50 | 0.080 |
Why?
| | Diabetes Mellitus | 2 | 2016 | 1107 | 0.070 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2012 | 268 | 0.070 |
Why?
| | Mice | 2 | 2024 | 18493 | 0.070 |
Why?
| | Health Promotion | 1 | 2015 | 790 | 0.070 |
Why?
| | Epidemiology | 1 | 2008 | 32 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2131 | 0.070 |
Why?
| | India | 2 | 2021 | 221 | 0.060 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1997 | 237 | 0.060 |
Why?
| | Smoking Cessation | 1 | 2011 | 441 | 0.060 |
Why?
| | Cytomegalovirus | 1 | 1988 | 172 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1415 | 0.060 |
Why?
| | Testicular Neoplasms | 1 | 1988 | 111 | 0.060 |
Why?
| | Patient Selection | 1 | 2011 | 746 | 0.060 |
Why?
| | Human T-lymphotropic virus 1 | 2 | 1999 | 34 | 0.060 |
Why?
| | Nucleoside-Triphosphatase | 1 | 2006 | 13 | 0.060 |
Why?
| | RNA Helicases | 1 | 2006 | 27 | 0.060 |
Why?
| | Flavivirus | 1 | 2006 | 19 | 0.060 |
Why?
| | Waist-Hip Ratio | 2 | 2016 | 37 | 0.060 |
Why?
| | Viral Nonstructural Proteins | 1 | 2006 | 64 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1798 | 0.050 |
Why?
| | Binomial Distribution | 1 | 2024 | 8 | 0.050 |
Why?
| | Spatial Analysis | 1 | 2024 | 21 | 0.050 |
Why?
| | Georgia | 1 | 2024 | 80 | 0.050 |
Why?
| | Germany | 1 | 2024 | 140 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2791 | 0.050 |
Why?
| | Lipids | 2 | 2022 | 723 | 0.050 |
Why?
| | Appointments and Schedules | 1 | 2024 | 97 | 0.050 |
Why?
| | Insulin | 3 | 2021 | 2526 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2012 | 1122 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2018 | 17561 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 162 | 0.050 |
Why?
| | Heartburn | 1 | 2021 | 12 | 0.040 |
Why?
| | Nutritional Requirements | 1 | 2021 | 78 | 0.040 |
Why?
| | Maryland | 1 | 2021 | 67 | 0.040 |
Why?
| | Hospitalization | 2 | 2024 | 2495 | 0.040 |
Why?
| | Gout | 1 | 2021 | 34 | 0.040 |
Why?
| | Hunger | 1 | 2021 | 56 | 0.040 |
Why?
| | American Heart Association | 1 | 2023 | 363 | 0.040 |
Why?
| | Iron | 1 | 2023 | 361 | 0.040 |
Why?
| | Africa, Eastern | 1 | 2020 | 12 | 0.040 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 2 | 1991 | 17 | 0.040 |
Why?
| | Transportation | 1 | 2020 | 56 | 0.040 |
Why?
| | Capital Financing | 1 | 2020 | 7 | 0.040 |
Why?
| | Causality | 1 | 2020 | 129 | 0.040 |
Why?
| | Tuberculin | 1 | 1999 | 8 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 484 | 0.040 |
Why?
| | Hepacivirus | 2 | 1998 | 243 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 221 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2080 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2019 | 119 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 104 | 0.040 |
Why?
| | Meconium | 1 | 2018 | 9 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 1998 | 28 | 0.040 |
Why?
| | Oncogene Proteins, Viral | 1 | 1998 | 20 | 0.040 |
Why?
| | Th1 Cells | 1 | 1999 | 139 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 166 | 0.030 |
Why?
| | Diet, Western | 1 | 2019 | 88 | 0.030 |
Why?
| | Virus Latency | 1 | 1998 | 93 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2022 | 583 | 0.030 |
Why?
| | Aged, 80 and over | 5 | 1997 | 8429 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 119 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 410 | 0.030 |
Why?
| | Sex Distribution | 2 | 2014 | 390 | 0.030 |
Why?
| | Calcium | 1 | 2023 | 1197 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 529 | 0.030 |
Why?
| | Immunologic Memory | 1 | 1999 | 371 | 0.030 |
Why?
| | Mucins | 1 | 2016 | 75 | 0.030 |
Why?
| | Deltaretrovirus Antibodies | 1 | 1996 | 1 | 0.030 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2016 | 57 | 0.030 |
Why?
| | Cancer Survivors | 1 | 2021 | 347 | 0.030 |
Why?
| | Viral Proteins | 1 | 1998 | 353 | 0.030 |
Why?
| | Health Care Costs | 1 | 2019 | 428 | 0.030 |
Why?
| | Receptors, GABA-A | 1 | 1996 | 138 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 797 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2018 | 347 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 520 | 0.030 |
Why?
| | Disease Transmission, Infectious | 1 | 1996 | 69 | 0.030 |
Why?
| | Educational Status | 1 | 2017 | 475 | 0.030 |
Why?
| | Dominican Republic | 1 | 2015 | 29 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1504 | 0.030 |
Why?
| | New York | 1 | 2015 | 128 | 0.030 |
Why?
| | Cerebellum | 1 | 1996 | 227 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 506 | 0.030 |
Why?
| | RNA, Viral | 1 | 1998 | 695 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2014 | 46 | 0.030 |
Why?
| | Gene Products, tax | 2 | 1991 | 15 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2015 | 120 | 0.030 |
Why?
| | Hepatitis B | 1 | 1995 | 66 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2019 | 625 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2015 | 361 | 0.030 |
Why?
| | Poverty | 1 | 2017 | 533 | 0.020 |
Why?
| | HTLV-I Antigens | 2 | 1991 | 2 | 0.020 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 2 | 1991 | 12 | 0.020 |
Why?
| | Communication | 1 | 2020 | 988 | 0.020 |
Why?
| | Colorado | 1 | 2023 | 4591 | 0.020 |
Why?
| | HIV Seroprevalence | 1 | 1992 | 4 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 2017 | 0.020 |
Why?
| | Serologic Tests | 1 | 1992 | 54 | 0.020 |
Why?
| | Forestry | 1 | 1992 | 4 | 0.020 |
Why?
| | Fisheries | 1 | 1992 | 3 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 1991 | 5 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1444 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1992 | 43 | 0.020 |
Why?
| | Homosexuality | 2 | 1992 | 18 | 0.020 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 1991 | 22 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 381 | 0.020 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1991 | 4 | 0.020 |
Why?
| | Bisexuality | 2 | 1992 | 41 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1995 | 379 | 0.020 |
Why?
| | Capsid | 1 | 1991 | 94 | 0.020 |
Why?
| | Agriculture | 1 | 1992 | 94 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 2006 | 2886 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3445 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 1991 | 168 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1996 | 2812 | 0.020 |
Why?
| | Dysgerminoma | 1 | 1988 | 6 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 2134 | 0.020 |
Why?
| | Sexual Behavior | 1 | 1992 | 502 | 0.020 |
Why?
| | Immunoglobulin A | 1 | 1989 | 214 | 0.020 |
Why?
| | Neurons | 1 | 1996 | 1672 | 0.020 |
Why?
| | Science | 1 | 2008 | 55 | 0.020 |
Why?
| | United Kingdom | 1 | 2008 | 390 | 0.020 |
Why?
| | History, 20th Century | 1 | 2008 | 333 | 0.020 |
Why?
| | Teratoma | 1 | 1988 | 124 | 0.020 |
Why?
| | Risk | 1 | 1989 | 927 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3216 | 0.010 |
Why?
| | Neoplasms | 1 | 2021 | 2946 | 0.010 |
Why?
| | HIV-1 | 1 | 1992 | 917 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 387 | 0.010 |
Why?
| | Health Personnel | 1 | 1992 | 759 | 0.010 |
Why?
| | Virus Replication | 1 | 1987 | 521 | 0.010 |
Why?
| | Recombinant Proteins | 2 | 1999 | 1371 | 0.010 |
Why?
| | Transcription Factors | 1 | 1989 | 1747 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1999 | 4170 | 0.010 |
Why?
| | Tritium | 1 | 1999 | 67 | 0.010 |
Why?
| | Thymidine | 1 | 1999 | 60 | 0.010 |
Why?
| | Mycobacterium bovis | 1 | 1999 | 15 | 0.010 |
Why?
| | BCG Vaccine | 1 | 1999 | 27 | 0.010 |
Why?
| | Interleukin-12 | 1 | 1999 | 115 | 0.010 |
Why?
| | Erythema | 1 | 1998 | 28 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 1999 | 126 | 0.010 |
Why?
| | Blotting, Western | 2 | 1991 | 1186 | 0.010 |
Why?
| | Interleukin-2 | 1 | 1999 | 440 | 0.010 |
Why?
| | Cell Division | 1 | 1999 | 758 | 0.010 |
Why?
| | Greece | 1 | 1997 | 9 | 0.010 |
Why?
| | Molecular Weight | 1 | 1996 | 313 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1999 | 786 | 0.010 |
Why?
| | Hepatitis Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1995 | 17 | 0.010 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 1995 | 17 | 0.010 |
Why?
| | Hepatitis B virus | 1 | 1995 | 33 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 1995 | 172 | 0.010 |
Why?
| | Eye Diseases | 1 | 1995 | 98 | 0.010 |
Why?
| | Retroviruses, Simian | 1 | 1991 | 1 | 0.010 |
Why?
| | Genes, pX | 1 | 1991 | 2 | 0.010 |
Why?
| | Life Style | 1 | 1995 | 502 | 0.010 |
Why?
| | Papio | 1 | 1991 | 70 | 0.010 |
Why?
| | Mexico | 1 | 1992 | 233 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1995 | 412 | 0.010 |
Why?
| | Agglutination Tests | 1 | 1991 | 4 | 0.010 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 1990 | 6 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1996 | 2542 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1991 | 165 | 0.010 |
Why?
| | Lymphocytes | 1 | 1991 | 378 | 0.000 |
Why?
| | DNA, Viral | 1 | 1991 | 357 | 0.000 |
Why?
| | Antibody Formation | 1 | 1991 | 288 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 66 | 0.000 |
Why?
| | Precipitin Tests | 1 | 1989 | 90 | 0.000 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 332 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1991 | 1046 | 0.000 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 849 | 0.000 |
Why?
| | Base Sequence | 1 | 1991 | 2175 | 0.000 |
Why?
| | Rats | 1 | 1996 | 5613 | 0.000 |
Why?
| | Alcohol Drinking | 1 | 1995 | 858 | 0.000 |
Why?
| | Family | 1 | 1991 | 689 | 0.000 |
Why?
| | Trans-Activators | 1 | 1989 | 398 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 3022 | 0.000 |
Why?
|
|
Mueller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|